ketamine has been researched along with Nerve Degeneration in 30 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 5.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Ketamine post-SE onset treatment prevented neuronal death in all regions assessed." | 5.38 | Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. ( Córdova, SD; de Oliveira, DL; Loss, CM, 2012) |
| " This article discusses the limitations of the published animal research, the challenges in extrapolating such data to humans, the need for further animal and human investigations, and the potential adverse effect on current clinical practice that might result, should the use of ketamine be restricted or the drug removed from the market." | 2.45 | Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. ( Coté, CJ; Green, SM, 2009) |
| "Parkinson's disease is a chronic neurodegenerative disorder characterized by cardinal motor features, such as bradykinesia, but also vocal deficits (e." | 1.48 | Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. ( Andreatini, R; Bruginski, E; Campos, FR; de Almeida Soares Hocayen, P; Kanazawa, LKS; Miyoshi, E; Schwarting, RKW; Stern, CAJ; Vecchia, DD; Vital, MABF; Wendler, E; Wöhr, M, 2018) |
| "Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the population worldwide." | 1.39 | Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice. ( Cao, X; Hou, Y; Liu, Y; Mao, Z; Wu, C; Xie, G; Yang, J; Zhang, H; Zhao, Y, 2013) |
| "Ketamine is an anaesthetic and analgesic drug used in research and clinical practice." | 1.39 | A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: An animal study. ( Antunes, LM; Ribeiro, PO; Rodrigues, PC; Valentim, AM, 2013) |
| "Ketamine was administered by IV infusion for 5 h to postnatal day 6 rhesus neonates or to pregnant rhesus females at 120 days' gestation (full term = 165 days)." | 1.38 | Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. ( Avidan, MS; Brambrink, AM; Creeley, CE; Dissen, GA; Evers, AS; Farber, NB; Martin, LD; Olney, JW; Smith, DJ, 2012) |
| "Ketamine post-SE onset treatment prevented neuronal death in all regions assessed." | 1.38 | Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. ( Córdova, SD; de Oliveira, DL; Loss, CM, 2012) |
| "Whether aromatization by glia affects gliosis itself or the initiation/maintenance of the WSD remains unknown." | 1.35 | Inhibition of injury-induced glial aromatase reveals a wave of secondary degeneration in the songbird brain. ( Bailey, DJ; Saldanha, CJ; Walters, BJ; Wynne, RD, 2008) |
| "R(-)-Ketamine was ineffective after both types of injury." | 1.29 | The effects of ketamine-isomers on neuronal injury and regeneration in rat hippocampal neurons. ( Georgieff, M; Himmelseher, S; Pfenninger, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.67) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, F | 1 |
| Wang, S | 1 |
| Lv, C | 1 |
| Zhang, M | 1 |
| Yang, L | 1 |
| Guo, X | 1 |
| Vecchia, DD | 1 |
| Kanazawa, LKS | 1 |
| Wendler, E | 1 |
| de Almeida Soares Hocayen, P | 1 |
| Bruginski, E | 1 |
| Campos, FR | 1 |
| Stern, CAJ | 1 |
| Vital, MABF | 1 |
| Miyoshi, E | 1 |
| Wöhr, M | 1 |
| Schwarting, RKW | 1 |
| Andreatini, R | 1 |
| Hou, Y | 1 |
| Zhang, H | 1 |
| Xie, G | 1 |
| Cao, X | 1 |
| Zhao, Y | 1 |
| Liu, Y | 1 |
| Mao, Z | 1 |
| Yang, J | 1 |
| Wu, C | 1 |
| Ribeiro, PO | 1 |
| Rodrigues, PC | 1 |
| Valentim, AM | 1 |
| Antunes, LM | 1 |
| Huang, C | 1 |
| Zhang, X | 4 |
| Zheng, J | 1 |
| Chen, C | 1 |
| Chen, Y | 1 |
| Yi, J | 1 |
| Slikker, W | 4 |
| Liu, F | 1 |
| Rainosek, SW | 1 |
| Patterson, TA | 2 |
| Sadovova, N | 2 |
| Hanig, JP | 2 |
| Paule, MG | 3 |
| Wang, C | 4 |
| Song, C | 2 |
| Chen, K | 1 |
| Green, SM | 1 |
| Coté, CJ | 1 |
| Zou, X | 1 |
| Divine, RL | 1 |
| Ullah, N | 1 |
| Ullah, I | 1 |
| Lee, HY | 1 |
| Naseer, MI | 1 |
| Seok, PM | 1 |
| Ahmed, J | 1 |
| Kim, MO | 1 |
| Brambrink, AM | 1 |
| Evers, AS | 1 |
| Avidan, MS | 1 |
| Farber, NB | 1 |
| Smith, DJ | 1 |
| Martin, LD | 1 |
| Dissen, GA | 1 |
| Creeley, CE | 1 |
| Olney, JW | 3 |
| Loss, CM | 1 |
| Córdova, SD | 1 |
| de Oliveira, DL | 1 |
| Hayashi, H | 1 |
| Dikkes, P | 1 |
| Soriano, SG | 2 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
| Anand, KJ | 2 |
| Rovnaghi, CR | 1 |
| Hickey, PR | 1 |
| Young, C | 1 |
| Jevtovic-Todorovic, V | 1 |
| Qin, YQ | 1 |
| Tenkova, T | 1 |
| Wang, H | 1 |
| Labruyere, J | 1 |
| Rudin, M | 1 |
| Ben-Abraham, R | 1 |
| Gazit, V | 1 |
| Tendler, Y | 1 |
| Tashlykov, V | 1 |
| Katz, Y | 1 |
| Kozek, SA | 1 |
| Sator-Katzenschlager, S | 1 |
| Kress, HG | 1 |
| Majewski-Tiedeken, CR | 1 |
| Rabin, CR | 1 |
| Siegel, SJ | 1 |
| Wynne, RD | 1 |
| Walters, BJ | 1 |
| Bailey, DJ | 1 |
| Saldanha, CJ | 1 |
| Himmelseher, S | 1 |
| Pfenninger, E | 1 |
| Georgieff, M | 1 |
| Hergovich, N | 1 |
| Singer, E | 1 |
| Agneter, E | 1 |
| Eichler, HG | 1 |
| Graselli, U | 1 |
| Simhandl, C | 1 |
| Jilma, B | 1 |
| Vachon, P | 1 |
| Precht, W | 1 |
| Volkind, R | 1 |
| Blanks, RH | 1 |
| Beyers, TM | 1 |
| Richardson, JA | 1 |
| Prince, MD | 1 |
| Keilhoff, G | 1 |
| Wolf, G | 1 |
| Stastný, F | 1 |
| Clifford, DB | 1 |
| Zorumski, CF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study[NCT00881764] | 369 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
3 reviews available for ketamine and Nerve Degeneration
| Article | Year |
|---|---|
Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine.
Topics: Anesthetics, Dissociative; Animals; Apoptosis; Child; Emergency Medicine; Humans; Ketamine; Nerve De | 2009 |
Application of microPET imaging approaches in the study of pediatric anesthetic-induced neuronal toxicity.
Topics: Anesthetics; Animals; Apoptosis; Brain; Child; GABA Agonists; Humans; Image Processing, Computer-Ass | 2013 |
Strategies and experimental models for evaluating anesthetics: effects on the developing nervous system.
Topics: Anesthetics; Animals; Animals, Newborn; Behavior, Animal; Biomedical Research; Cell Death; Disease M | 2008 |
1 trial available for ketamine and Nerve Degeneration
| Article | Year |
|---|---|
Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Pressure; Cross-Over Studies; Drug Tolerance; Excitatory Amino Acid Antagonists; Heart | 2001 |
26 other studies available for ketamine and Nerve Degeneration
| Article | Year |
|---|---|
Lin28b and Sox2 regulate anesthesia-induced neural degeneration in neural stem cell derived neurons.
Topics: Anesthetics; Animals; Cell Differentiation; Female; Ketamine; Nerve Degeneration; Neural Stem Cells; | 2018 |
Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease.
Topics: Anhedonia; Animals; Depression; Disease Models, Animal; Gait; Imipramine; Ketamine; Male; Nerve Dege | 2018 |
Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice.
Topics: Animals; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Hippocampus; Immobilit | 2013 |
A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: An animal study.
Topics: Anesthetics, Dissociative; Animals; Behavior, Animal; Brain; Injections, Intraperitoneal; Ketamine; | 2013 |
Upregulation of miR-137 protects anesthesia-induced hippocampal neurodegeneration.
Topics: Anesthetics, Dissociative; Animals; cdc42 GTP-Binding Protein; Gene Expression Regulation; Hippocamp | 2014 |
Ketamine-Induced Toxicity in Neurons Differentiated from Neural Stem Cells.
Topics: Animals; Apoptosis; Astrocytes; Calcium; Cell Division; Cells, Cultured; Cerebral Cortex; Culture Me | 2015 |
Inhibition of long non-coding RNA IGF2AS protects apoptosis and neuronal loss in anesthetic-damaged mouse neural stem cell derived neurons.
Topics: Anesthetics, Dissociative; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cells, Cultured; D | 2017 |
Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain.
Topics: Anesthetics, Dissociative; Animals; Brain; Caspase 3; Cell Death; Fluoresceins; Humans; Ketamine; Ma | 2009 |
Protective function of nicotinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain.
Topics: Anesthetics, Dissociative; Animals; Animals, Newborn; Apoptosis; Ketamine; Nerve Degeneration; Neuro | 2012 |
Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Female; Fetus; Infusions, Intravenous; Ketamine; Macaca | 2012 |
Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats.
Topics: Animals; Anxiety; Brain; Convulsants; Ketamine; Male; Nerve Degeneration; Neuroprotective Agents; Pi | 2012 |
Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain.
Topics: Animals; Animals, Newborn; Brain; Ketamine; Nerve Degeneration; Rats; Rats, Sprague-Dawley; Receptor | 2002 |
Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.
Topics: Animals; Animals, Newborn; Apoptosis; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2004 |
Of mice and men: should we extrapolate rodent experimental data to the care of human neonates?
Topics: Anesthesia; Anesthetics; Anesthetics, Dissociative; Animals; Blood Gas Analysis; Food Deprivation; H | 2005 |
Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain.
Topics: Animals; Apoptosis; Blood Gas Analysis; Brain; Caspase 3; Caspases; Cell Count; Cell Death; Drug Int | 2005 |
Single-dose ketamine administration induces apoptosis in neonatal mouse brain.
Topics: Animals; Animals, Newborn; Apoptosis; Behavior, Animal; Brain; Coloring Agents; Eosine Yellowish-(YS | 2005 |
Intrathecal S(+)-ketamine in refractory neuropathic cancer pain.
Topics: Anesthetics, Dissociative; Brain Stem; Gliosis; Humans; Injections, Spinal; Ketamine; Male; Neoplasm | 2006 |
Anesthetic neurotoxicity in newborns: should we change clinical practice?
Topics: Anesthetics; Anesthetics, Dissociative; Animals; Humans; Infant, Newborn; Ketamine; Nerve Degenerati | 2007 |
Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains.
Topics: Animals; Caspase 3; Cell Death; Cell Nucleus; Evoked Potentials; Excitatory Amino Acid Antagonists; | 2008 |
Inhibition of injury-induced glial aromatase reveals a wave of secondary degeneration in the songbird brain.
Topics: Animals; Apoptosis; Aromatase; Aromatase Inhibitors; Brain; Data Interpretation, Statistical; Enzyme | 2008 |
The effects of ketamine-isomers on neuronal injury and regeneration in rat hippocampal neurons.
Topics: Anesthetics, Dissociative; Animals; Axons; Cell Survival; Cells, Cultured; Dendrites; Glutamic Acid; | 1996 |
Self-mutilation in rabbits following intramuscular ketamine-xylazine-acepromazine injections.
Topics: Acepromazine; Anesthetics, Combined; Animals; Axons; Injections, Intramuscular; Ketamine; Nerve Dege | 1999 |
Functional organization of the vestibular input to the anterior and posterior cerebellar vermis of cat.
Topics: Animals; Axonal Transport; Cats; Cerebellar Cortex; Electric Stimulation; Evoked Potentials; Horsera | 1977 |
Axonal degeneration and self-mutilation as a complication of the intramuscular use of ketamine and xylazine in rabbits.
Topics: Animals; Axons; Injections, Intramuscular; Ketamine; Nerve Degeneration; Rabbits; Self Mutilation; X | 1991 |
Effects of MK-801, ketamine and alaptide on quinolinate models in the maturing hippocampus.
Topics: Animals; Cell Hypoxia; Dizocilpine Maleate; Hippocampus; Injections, Intraventricular; Ketamine; Mal | 1991 |
Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures.
Topics: Animals; Anticonvulsants; Bicuculline; Cerebral Cortex; Dibenzocycloheptenes; Dizocilpine Maleate; E | 1989 |